Breast Neoplasms Clinical Trial
Official title:
Randomized Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction
Introduction: physical therapy is essential in preventing motor and functional complications after breast cancer surgery. However, there is no prospective randomized study of different physiotherapy approaches in patients undergoing breast cancer surgery with immediate reconstruction. Objectives: to evaluate two physical therapy protocols in patients after breast cancer surgery with immediate reconstruction. A group with shoulder exercises with limited range of motion (ROM) at 90 degrees up to a month after surgery and a group with limited ROM only up to 15 days after surgery. Specific objectives: to evaluate shoulder ROM and pain one week before the surgery on average, and 07, 15, 30, 60, 90 and 180 days after surgery; assess motor function one week before the surgery on average, and 30 and 90 days after surgery; evaluate dehiscence and seroma 07, 15, 30, 60 and 90 days after surgery; associate incidence of seroma and dehiscence with preoperative risk factors and compare all variables (shoulder ROM, pain, motor function, seroma and dehiscence) between the two groups. Methods: women with breast cancer, who will be submitted to breast surgery (radical or conservative), followed by immediate reconstruction: alloplastic (tissue expander or breast implant) or oncoplastic (breast reduction or contralateral symmetrization) will be included. Patients that will be submitted to bilateral oncology surgery, reconstruction with autologous tissue or breast surgery without reconstruction will not be included. Patients will be recruited just after surgery scheduling and will undergo preoperative evaluation. At this moment, preoperative analysis will be conducted with personal data and medical history. Patients will undergo new assessments 07, 15, 30, 60, 90 and 180 days after surgery. All patients will receive standard physiotherapy treatment for women undergoing breast reconstruction from Physical Therapy Sector. The protocol consists of early exercise, limited to 90° of shoulder ROM, starting the day after the surgery and repeated 7 days after surgery. After 15 days of surgery, the patients will be randomized into two treatment protocols. One group will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain. The other group will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), they will also be allowed to move the shoulder with no restriction. The evaluation of the presence of dehiscence and seroma will occur by inspection and palpation. Shoulder ROM will be investigated through active goniometry of flexion, extension, adduction, abduction, internal rotation and external rotation. The pain will be assessed with the Verbal Numerical Scale from 0 to10 and upper limb function through the DASH (Disabilities of the Arm, Shoulder and Hand Questionnaire) questionnaire.
Methods:
Patients will be recruited just after surgery scheduling. They will undergo preoperative
evaluation one week before the surgery on average. At this moment, preoperative analysis will
be conducted with personal data and medical history. Patients will undergo new assessments
07, 15, 30, 60, 90 and 180 days after surgery, periods that will be described as PO 07, PO
15, PO 30, PO 60, PO 90 and PO 180.
All patients will receive standard physiotherapy treatment for women undergoing breast
reconstruction from Physical Therapy Sector of Mastology Discipline of the Department of
Gynecology of Federal University of São Paulo. The protocol consists of early exercise,
limited to 90° of shoulder range of motion (ROM), starting the day after the surgery and
repeated 7 days after surgery.
After 15 days of surgery, the patients will be randomized into two treatment protocols.
However, because of the existence of different types of reconstructive surgery, randomization
will performed from two groups:
- Alloplastic group: patients who will undergo reconstruction with tissue expander or
breast implant
- Oncoplastic Group: patients who will undergo mammaplasty and / or contralateral
symmetrization
Computer random sequence will be used for randomization, in which each group will be
randomized to Group A or Group B.
- Subgroup A: Patients will start to perform exercises with free shoulder ROM. Patients
will be told only to limit the movement if they feel pain.
- Subgroup B: Patient will keep shoulder exercises limited to 90° up to 30 days after
surgery. At that moment (one month after surgery), then patients will also be allowed to
move the shoulder with no restriction
At the end of randomization there will be four subgroups: alloplastic A, alloplastic B,
oncoplastic A and oncoplastic B
Outcomes:
1. Shoulder range of motion:
The shoulder ROM will be assessed with a goniometer for flexion, extension, adduction,
abduction, internal rotation and external rotation. The movements will be performed
actively. The patient will be positioned in the sitting position. To assess shoulder
flexion, the upper limb will be in neutral position with elbow extension. Patient will
be asked to raise the arm forward, close to the body. To assess extension, the arm will
be positioned with 90° of elbow flexion and the patient will be asked to take the arm
back. For adduction, the patient will be with 90° of shoulder flexion with the palm down
and patient will be told to move the arm medially. For the study of the upper limb
abduction, the limb will be in supination and elbow extension and the patient will be
asked to raise the arm to the side, along the trunk line toward the ear. For the
evaluation of internal rotation and external rotation the upper limb will be placed in
90° of shoulder abduction and 90° of elbow flexion. The patient will be asked to rotate
the shoulder internally and externally, respectively.
2. Pain:
The pain will be evaluated with the Verbal Scale of Pain from zero to ten, where zero is
no pain and ten is unbearable pain. The patient will be asked if there is pain at the
moment of evaluation , and to describe the place and the degree of the pain.
3. Upper limbs function:
To investigate the motor shoulder function DASH (Disabilities of the Arm, Shoulder and
Hand Questionnaire) questionnaire will be used. It assesses the functional capacity in
upper limb diseases and measures the skills to do certain activities, as well as the
symptoms. It consists of 30 self-administered questions and two optional modules, for
sports or musical activities and work activities. The 30 items evaluate the degree of
difficulty in the performance of activities; the intensity of the symptoms of pain,
weakness, stiffness and numbness; the commitment of social activities; the difficulty to
sleep and psychological commitment by reference to the week preceding the instrument
application. The final score ranges from zero to one hundred, and the higher the score,
the higher the upper limb dysfunction (arm, shoulder or hand).
4. Dehiscence:
Dehiscence wil be assessed by inspection and palpation. It will be described "presence"
or "absence" of dehiscence and its location. The wound conditions will be described,
with observation of necrosis and infection. Signs of infection such as redness,
hyperthermia and secretion will be reported. The size of dehiscence will be described:
in relation to the amount of opening points, in case of several opened points; or in
centimeters (assessed per tape). Photographic record of dehiscence will be done, for
better analysis and comparison of evolution. A Nikon Coolpix S3000 camera will be used.
5. Seroma:
The seroma evaluation will be performed by inspection and palpation. There will be
description of "presence" or "absence" of seroma, location and the number of punctures made
by the medical team and drained quantity, when necessary.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
| Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
| Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
| Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
| Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
| Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03698942 -
Delphinus SoftVueâ„¢ ROC Reader Study
|
||
| Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
| Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
| Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
| Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 | |
| Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A | |
| Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A |